Mylan to pay $30 million U.S. SEC fine related to EpiPen overcharge probe
Mylan NV has agreed to pay a $30 million fine to settle U.S. Securities and Exchange Commission charges it hid from investors the impact of a federal probe into the drugmaker's overbilling the government for its EpiPen allergy treatment.